Open an account

Ascentage Pharma Group International

AAPG · HONG

$15.44+$0.52 (+3.49%)TodayMarket closed ·
Prev close $14.92

About AAPG

Ascentage Pharma Group International Co., Ltd. is a clinical-stage biotechnology company. The company is headquartered in Suzhou, Jiangsu and currently employs 767 full-time employees. The company went IPO on 2019-10-28. The firm's main products include Olverembatinib (HQP1351), Lisaftoclax (APG-2575), Alrizomadlin (APG-115), Pelcitoclax (APG-1252), APG-5918, and APG-2449. The firm's products are primarily used to treat chronic myeloid leukemia (CML), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), myelodysplastic syndrome (MDS) and multiple myeloma (MM). The firm primarily conducts its businesses in domestic market.

Employees
767
Headquarters
Suzhou, Jiangsu
Listed
Oct 28, 2019
Sector
Health Care
Industry
Biotechnology
Website
ascentage.cn

AAPG key statistics

Market cap
10.60B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.92K
Volume
9.39K
Open price
$15.46
High today
$15.44
Low today
$15.21
52 Week high
$35.46
52 Week low
$14.46

Ascentage Pharma Group International (AAPG) at a glance

Ascentage Pharma Group International (AAPG) last traded at $15.44, with a market cap of 10.60B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $15.21 and $15.44. The current price is 1.5% above the day's low and 0.0% below its high.

Volume so far is 9.39K shares, in line with the average of 7.92K shares a day.

Over the past year Ascentage Pharma Group International has ranged from $14.46 to $35.46, and now sits 5% of the way up that range.

The average analyst price target is $26.01, 68.4% above the current price, from 10 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 10 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 4 analystsAvg $26.01
Low
$25.75
Now
$15.44
High
$26.77

AAPG news

  • Vandana Singh

    Ascentage Pharma Stock Could More Than Double: Analyst

  • Transcript: Ascentage Pharma Group H1 2026 Earnings Conference Call

  • Press releaseGlobe Newswire

    Ascentage Pharma Reports 2026 Interim Unaudited Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    CORRECTION: Ascentage Pharma to Report 2026 Six Month Interim Results and Provide Corporate Update on August 19, 2026

  • Avi Kapoor

    Why nCino Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket

  • Press releaseGlobe Newswire

    Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business Updates

  • Press releaseGlobe Newswire

    Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026

  • Avi Kapoor

    Novo Nordisk, Sable Offshore, StoneCo And Other Big Stocks Moving Higher On Tuesday

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.